Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolon, a provider in metabolomics, biomarker discovery and biochemical analysis, has received US Patent 7,910,301 ' Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics' from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The ‘301 patent is directed to identifying small molecules that are affected by using metabolomics.
It provides a method to evaluate chemical agents for drug effects and toxicity, thereby facilitating pre-clinical and clinical drug development activities.
Metabolon is the exclusive license holder of the Daouk-Kristal patent family which is comprised of early, pioneering patents and patent applications which provide fundamental IP in the field of metabolomics.
The patent extends Metabolon’s IP related to the use of metabolomics beyond disease biomarker discovery into uses of metabolomics for drug discovery and development.
Metabolon previously issued patents for determining biomarkers for all diseases, including cancer, metabolic disorders, and neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, depression and schizophrenia.
Metabolon also owns patents relating to disease biomarkers and for software designed for analyzing metabolomics data.